Fluorescent tracer agents coupled with transdermal detection technology enable physiological monitoring.
Bright fluorescent agents designed not to interact with the body are sensed through the skin.
New clinical applications for fluorescent tracer agent-based systems are in development.
Clinical and preclinical studies are underway to advance the use of fluorescence to measure and monitor disease progression.
Composition of matter, algorithm, and method patents are a platform for continued innovation.
Leading academic centers, research institutes, contract research organizations and pharmaceutical companies worldwide rely on MediBeacon technology.
Clinically practical solutions which can reduce the cost of healthcare while improving the standard of care are the goal.
Fluorescent agents engineered to not interact with the body have the potential to enable measurement and monitoring of vital organ systems.
Measurement of GFR is widely accepted as the best indicator of kidney function. A clinically practical and accurate real-time point of care methodology holds promise.
Increased intestinal permeability is implicated in inflammatory bowel disease. Rapid assessment of gut barrier function is a focus.
Fluorescent agent angiography has the potential to aid in diagnosis and monitoring of vasculature leakage seen in Diabetic Retinopathy, Macular Degeneration and Retinal Vasculitis.
Intraoperative identification of ureter or ureteral injury is critical to prevent serious complications. Use of fluorescent agents could potentially aid in surgical visualization.
Potential medical applications for fluorescent tracer agent-based systems are wide ranging and target important unmet patient needs.
Fluorescent tracer agent-based systems target growing unmet patient needs globally.
Scientists who have made the application of fluorescent technology in healthcare their life’s work are behind MediBeacon’s medical innovations.
Investment in fluorescence-based systems target multiple multi-billion dollar unmet medical needs.
Technology whose development began inside leading medical technology companies is nearing human application today.
Industry leaders including scientists and clinicians are behind fluorescence enabled technology that has the potential to impact global health.
Our approach to quality concentrates on the integrity of processes and preventive measures.
The latest developments are global in scope.
Edward Jones and St. Louis Economic Council Unveil Business Competition
(ST. LOUIS, April 3, 2013) - MediBeacon LLC, winner of the 2012 edition of the St. Louis County Economic Council’s competition set the stage for Edward Jones and St. Louis County Economic Council to unveil the 2013 St. Louis Startup Challenge. Edward Jones and St. Louis County Economic Council unveiled the St. Louis Startup Challenge. Sponsored by leading companies in St. Louis, the Startup Challenge highlights local entrepreneurs, helps them develop their venture, and rewards the best-of-the-best in an all-out public celebration.
MediBeacon CEO, Steve Hanley was invited to provide an update on The Company and fielded questions in advance of the official announcement of the 2013 St. Louis Startup Challenge, which took place at the Nine Network of Public Media in St. Louis during the 1 Million Cups™ event held on April 3, 2013.
Since winning the 2012 competition MediBeacon has gained valuable insight from a network of clinicians. MediBeacon now has 30 granted patents. The Company is gaining a further appreciation of the unmet need for real-time point-of-care renal function monitoring as a result of discussions with a wide range of clinicians as well as medical technology focused investors.
A video promotion of the 2013 St. Louis Startup Challenge featuring MediBeacon CEO, Steve Hanley is available below:
# # #
Office - 314-269-5808
Email - firstname.lastname@example.org
1100 Corporate Square Drive
Helix Center, Suite 229
St Louis MO 63132
1100 Corporate Square Drive
St. Louis, MO 63132
P: (314) 269-5808
P: +49 (0)621-150283-15
*MediBeacon products are in various stages of clinical development and are not yet approved for human use.
**The Transdermal GFR Measurement System (TGFR) is intended to measure Glomerular Filtration Rate (GFR) in patients with impaired or normal renal function. References on this website to measured kidney function and measured renal function refer to the measured GFR.